4D Molecular Therapeutics Grants 141,100 RSUs to 14 New Employees
Updated
Updated · GlobeNewswire · May 15
4D Molecular Therapeutics Grants 141,100 RSUs to 14 New Employees
1 articles · Updated · GlobeNewswire · May 15
Summary
May 12 grants covered 141,100 restricted stock units awarded to 14 newly hired non-executive employees, the company said.
The awards were issued under 4D Molecular Therapeutics' amended 2025 Employment Inducement Award Plan and structured to attract recruits under Nasdaq Rule 5635(c)(4).
4DMT is a late-stage biotech whose lead candidate, 4D-150 for wet age-related macular degeneration, is in Phase 3 development, while 4D-710 targets cystic fibrosis.
None of the company's product candidates has been approved for marketing by the FDA or any other regulator.